Systemic inflammation in traumatic brain injury predicts poor cognitive function

Wende Xu1 | Shenglei Yue2 | Peng Wang1 | Bin Wen1 | Xiaojue Zhang3

1Department of Neurosurgery, First People's Hospital of Tianshui, Tianshui City, Gansu Province, PR China
2Department of Neurosurgery, Sishui County Hospital, Jining City, Shandong Province, PR China
3Department of Neurosurgery, Lanling County People's Hospital, Linyi City, Shandong Province, PR China

Correspondence
Xiaojue Zhang, Department of Neurosurgery, Lanling County People's Hospital, No. 4, Jiankang St, Middle Section of Huibao Rd, Lanling County, Linyi City, Shandong Province 277799, PR China.
Email: zzxjxiaojue@163.com

Abstract

Background: Traumatic brain injury (TBI) impairs cognitive function. Systemic inflammation plays an important role in cognitive deficits. It remains unclear if systemic inflammation in TBI is associated with poor cognitive function.

Methods: From January 2018 to December 2020, two groups of subjects were recruited: patients with TBI (n = 120), and healthy control (n = 120), followed up to 3 months. Blood was collected from TBI patients and healthy control, and serum inflammatory cytokines including interferon-α (IFN-α), interleukin-1β (IL-1β), IL-6, IL-8, IL-10, and tumor necrosis factor-α (TNF-α) were measured at baseline and end of 3 months. Multivariate regression was used for analysis for the relationship between cognitive function and inflammatory cytokines.

Results: Inflammatory cytokines were higher in patients with brain injury and remained high at end of 3 months. Some cytokines such as IFN-α, IL-1β, IL-6, and TNF-α were associated with worsening memory and predicted poor performance.

Conclusion: Systemic inflammation in patients with TBI predicts poor cognitive function.

Keywords
cognitive function, systemic inflammation, traumatic brain injury

1 | INTRODUCTION

Traumatic brain injury (TBI) caused by the external mechanical force is a diverse group of brain injuries such as skull or brain damage, strong rotations of head, or penetration of objects in the cranium.1 TBI varies in cause, severity, pathogenesis, and clinical outcome, which is the most common cause of long-term disability and death among children and young adults.2 It is reported that about 5.48 million people suffer from severe TBI each year, leading to an enormous socioeconomic and healthcare burden.3 TBI may affect behavioral, cognitive, emotional, and psychological functions and life quality of patients.4,5 Most importantly, TBI contributes to cognitive dysfunction in the diseases including chronic traumatic encephalopathy, Alzheimer's disease, and Parkinson's disease.6–8 New strategies including PC-based rehabilitation or Virtual Reality Training (VRT) have been used to improve cognitive and behavioral skills in TBI patients.9–11

Inflammation can fight against invading pathogens and preserve healthy tissue while functions as a reactionary...
system to either aggravate or ameliorate tissue damage in pathological tissues. It is suggested that inflammation is a central component of the secondary injury to the central nervous system (CNS) after TBI, and inhibition of inflammation is regarded as a promising target for TBI treatment. A previous study provided the evidence that following therapeutic inhibition of inflammasome activation obviously reduces innate immune activation and severe TBI. However, few studies were conducted on the inflammation resulting in secondary brain damage. In this study, we evaluated the systemic inflammation in TBI patients and predicted the relationship between inflammation and cognitive functions in TBI patients.

2 | MATERIALS AND METHODS

2.1 | Patients

A total of 120 patients with TBI (age: 36.56 ± 8.21 years; 54.76% males), who attended our hospital from January 2018 to December 2020, were enrolled in this study. In addition, 120 healthy persons (age: 37.73 ± 9.1 years; 52.38% males) were included in this study. These patients and healthy controls had blood samples prospectively collected at admission and after 30 days of follow-up. This study was approved by the Ethics Committee of the First People’s Hospital of Tianshui, and informed consent was obtained from all patients and healthy control participants in this study.

Inclusion criteria: neurological diagnosis of mild to moderate TBI; ability to sit for at least 20 min; presence of mild to moderate cognitive impairment.

Exclusion criteria: age older than 80 years; presence of disabling sensory alterations and frequent episodes of recurrent; other medical and psychiatric illness.

2.2 | Enzyme-linked immunosorbent assay (ELISA) assay

A total of 5ml of venous blood was obtained from healthy controls and TBI patients, centrifuged at the speed of 3000 r/min for 10 min, and serum was collected. The expression levels of serum IFN-α, IL-1β, IL-6, IL-8, IL-10, and TNF-α were measured by ELISA kits (all from Merck-Millpore) according to manufacturers.

2.3 | Cognitive assessment

Montreal Cognitive Assessment (MoCA) was used to test cognitive function, which contained 30 items: short-term memory (5 points); visuospatial abilities via clock drawing (3 points), and a cube copy task (1 point); executive functioning via an adaptation of Trail Making Test Part B (1 point), phonemic fluency (1 point), and verbal abstraction (2 points); attention, concentration, and working memory via target detection (1 point), serial subtraction (3 points), digits forward (1 point), and digits backward (1 point); language via confrontation naming with low-familiarity animals (3 points), and repetition of complex sentences (2 points); and orientation to time and place (6 points).

2.4 | Data analysis

Data were analyzed using the Statistical Product and Service Solutions (SPSS) version 19.0 (SPSS, Inc.), and expressed as mean ± standard deviation (SD). A p < .05 was considered as statistically significant. Using SPSS, we performed the analysis of variance (ANOVA) to assess the difference at baseline and after 30 days of follow-up. Multivariable logistic regression was used to calculate adjusted odds ratios with 95% confidence intervals (CI) to examine the relationship between the risk of cognitive impairment and inflammatory cytokines.

3 | RESULTS

3.1 | General characteristic of patients

General characteristic of TBI patients and healthy controls was listed in Table 1. No significant differences were found in participant number (p = .000), age (p = .1424), sex (p = .1082), and education (p = .8613) between TBI patients and healthy controls at baseline. Interval from TBI patients was 3 ± 0.58 months. Twenty-eight cases of brain lesion occurred on cortical left, 6 cases on cortical right, 35 cases on subcortical left, and 51 cases on subcortical right.

3.2 | Changes of inflammation of TBI patients

The expression levels of proinflammatory cytokines, including IL-1β, IL-10, IL-6, IL-8, IFN-α, and TNF-α were detected in this study. As shown in Table 2, the levels of proinflammatory cytokines were significantly increased in TBI group compared to the control group (p < .001), indicating that TBI leads to inflammation in patients. Meanwhile, compared with TBI group, it was observed that the protein expressions of these proinflammatory cytokines induced by TBI were markedly reduced in the TBI group.
which was given a treatment after 30 days of follow up \( (p < .001) \), while the expressions were obviously higher that those in the healthy control group \( (p < .05) \). The results suggest that the inflammation is involved in TBI patients before or after treatment (Table 3).

### 3.3 Correlation between inflammation and cognitive function

First, we evaluated score distributions of the MoCA in TBI patients and healthy controls. The MoCA ≥15 points detected in healthy control (99.36%), TBI patients (95.62%), and TBI patients after treatment (98.35%). The MoCA ≥18 was 99.08%, 90.17%, 94.29% in healthy controls, TBI patients, and TBI patients after treatment, respectively. The MoCA ≥21 was 89.37%, 63.86%, 80.33% in above three groups.

Furthermore, the 95% CI for cognitive impairment and cytokines are presented in Table 4. Multivariate analysis showed that 95% CI of cytokines IL-6, IL-1β, TNF-α, IFN-α, and cognitive function was high, indicating a significant correlation between cognitive impairment and these cytokines. However, we observed a low 95% CI of cytokines IL-8 and IL-10 and cognitive function. It indicates systemic inflammation in patients with TBI predicts poor cognitive function.

### 4 DISCUSSION

Previous studies demonstrated that TBI initiates a secondary injury such as acute and chronic inflammatory events, thus aggravating outcome or promoting reparative processes.\(^\text{16}\) Another study suggested that inflammation is believed to participate in the pathophysiology of TBI.\(^\text{17}\) In a study in treatment strategies, it was demonstrated that a reduction in leukocyte infiltration into the post-injured brain improves both histopathological and functional outcome measures.\(^\text{18}\) It is now well accepted that inhibition of inflammation can improve the prognosis of TBI, and it is effective in the recovery of patients with TBI.\(^\text{19}\) In this study, it is confirmed that systemic inflammation may predict patients with TBI.

The Mini-Mental State Examination (MMSE) and MoCA are widespread and concise screening tools for the assessment of cognitive impairment that has a significant impact on the evaluation of age-related cognitive decline.\(^\text{20}\) Recently, the MoCA has been developed to detect mild cognitive impairment with a score range 0–30 in

### TABLE 1 Characteristics for both healthy control group and TBI patient group

| Items                        | Healthy control group | TBI patient group | \( p \) value |
|------------------------------|-----------------------|-------------------|--------------|
| Participants (number)        | 120                   | 120               | .000         |
| Age (years)                  | 36.56 ± 8.21          | 37.73 ± 9.1       | .1424        |
| Education (years)            | 16.25 ± 1.66          | 16.16 ± 2.03      | .8613        |
| Gender                       |                       |                   |              |
| Male                         | 63                    | 66                | .1082        |
| Female                       | 57                    | 54                | .1157        |
| Interval from TBI (mean in months) | 0            | 3 ± 0.58          | .0001        |
| Brain lesion site/side       |                       |                   |              |
| Cortical left                | 0                     | 28                | .0001        |
| Cortical right               | 0                     | 6                 | .0001        |
| Subcortical left             | 0                     | 35                | .0001        |
| Subcortical right            | 0                     | 51                | .0001        |

Abbreviation: TBI, traumatic brain injury.

### TABLE 2 Inflammation between health control group and TBI patient group

| Items          | Healthy control group | TBI patient group | TBI patient group after 30 days of follow up | \( p \) value |
|----------------|-----------------------|-------------------|---------------------------------------------|--------------|
| IL-6 (pg/ml)   | 42.29 ± 5.18          | 122 ± 7.85        | 122 ± 7.85                                  | <.05         |
| IL-8 (pg/ml)   | 35.73 ± 2.62          | 302 ± 12.26       | 146 ± 10.38                                 | <.05         |
| IL-10 (pg/ml)  | 34.33 ± 7.03          | 108.55 ± 10.37    | 75.45 ± 12.26                               | <.05         |
| IL-1β (pg/ml)  | 15.17 ± 1.26          | 28.87 ± 2.44      | 21.25 ± 2.49                                | <.05         |
| TNF-α (ng/ml)  | 11.06 ± 2.62          | 22.06 ± 4.37      | 16.45 ± 2.43                                | <.05         |
| IFN-α (ng/ml)  | 9.32 ± 1.35           | 18.24 ± 3.15      | 12.81 ± 3.66                                | <.05         |

Abbreviations: IFN-α, interferon-α; IL, interleukin; TBI, traumatic brain injury; TNF-α, tumor necrosis factor-α.
used to predict poor cognitive function. Inflammation can be
in synaptic inhibition.29

GABAergic neurons in the hippocampus due to a reduction
TNF

gested that an elevated expression of cytokines including
evaluate cognitive impairment. In the present
petition, verbal fluency, and abstraction.24 In the present
naming objects, memory, recall, attention, vigilance, re-
address orientation, drawing figures, processing speed,

China and other countries.21–23 In addition, MoCA can
address orientation, drawing figures, processing speed,
naming objects, memory, recall, attention, vigilance, re-
petition, verbal fluency, and abstraction.24 In the present
study, it was suggested that the MoCA is effective to
evaluate cognitive impairment.

Both clinical and experimental investigations have sug-
gested that an elevated expression of cytokines including
TNF-α, transforming growth factor-β (TGF-β), and IL-1β,
IL-6, and IL-10 were found after TBI.25–27 Cytokines acted as
classical neurotransmitters recruit additional blood-borne
neutrophils and monocytes into the injured tissue to activate
the inflammatory cascade.28 Chronic inflammation induced
by overexpression of IL-6 or TNF-α can promote the loss of
GABAergic neurons in the hippocampus due to a reduction
in synaptic inhibition.29–31 The expression of proin-
flammatory cytokine IL-1β from peripheral blood mono-
nuclear cells increases significantly 48–60 h after TBI and
contributes to the inflammatory events that lead to neuronal
loss.32,33 Also, an upregulation in serum expression of TNF-
α, IL-1β, IL-6, IL-8, and IL-10 in TBI patients is found
compared to the healthy control, and inflammation can be
used to predict poor cognitive function.

5 | CONCLUSIONS

This study suggests that inflammation may be a useful
biomarker for patients with TBI, and its inhibition poten-
tially leads to better cognitive and behavioral
outcomes. Further studies are needed to assess how to
inhibit inflammation to improve overall functional re-
covery and quality of life in TBI patients.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

AUTHOR CONTRIBUTIONS

All authors have read and approved the manuscript. Guar-
antor of integrity of the entire study: Wende Xu. Study
concepts: Wende Xu. Study design: Shenglei Yue. Definition
of intellectual content: Shenglei Yue. Literature research:
Peng Wang. Clinical studies: Peng Wang. Experimental
studies: Bin Wen. Data acquisition: Xiaojue Zhang. Data
analysis: Bin Wen. Statistical analysis: Xiaojue Zhang.
Manuscript preparation: Wende Xu, Panyi Zhang. Manu-
script editing: Wende Xu. Manuscript review: Wende Xu.

REFERENCES

1. Menon DK, Schwab K, Wright DW, Maas AI. Demographics
and Clinical Assessment Working Group of the International
and Interagency Initiative toward Common Data Elements for
Research on Traumatic Brain Injury and Psychological Health
Position statement: definition of traumatic brain injury. Arch
Phys Med Rehabil. 2010;91(11):1637-1640.
2. De Luca R, Maggio MG, Maresca G, et al. Improving cognitive
function after traumatic brain injury: a clinical trial on the
potential use of the semi-immersive virtual reality. Behav
Neurol. 2019;2019:9268179.
3. Iaccarino C, Carretta A, Nicolosi F, Morselli C. Epidemiology of
severe traumatic brain injury. J Neurosurg Sci. 2018;62(5):535-541.
4. Latella D, Maggio MG, de Luca R, et al. Changes in sexual
functioning following traumatic brain injury: an overview on a
neglected issue. J Clin Neurosci. 2018;58:1-6.
5. Maggio MG, de Luca R, Torrisi M, et al. Is there a correlation
between family functioning and functional recovery in pa-
tients with acquired brain injury? An exploratory study. Appl
Nurs Res. 2018;41:11-14.
6. Werner JK, Stevens RD. Traumatic brain injury: recent ad-
vances in plasticity and regeneration. Curr Opin Neurol. 2015;
28(6):565-573.
7. Smith DH, Johnson VE, Stewart W. Chronic neuropathologies
of single and repetitive TBI: substrates of dementia? Nat Rev
Neuro. 2013;9(4):211-221.
8. Corps KN, Roth TL, McGavern DB. Inflammation and neu-
roprotection in traumatic brain injury. JAMA Neurol. 2015;
72(3):355-362.
9. Algethamy H. Baseline predictors of survival, neurological recovery, cognitive function, neuropsychiatric outcomes, and return to work in patients after a severe traumatic brain injury. *Mater Sociomed*. 2020;32(2):148-157.

10. Chen SHA, Thomas JD, Glueckauf RL, Bracy OL. The effectiveness of computer-assisted cognitive rehabilitation for persons with traumatic brain injury. *Brain Inj*. 1997;11(3):197-210.

11. Aida J, Chau B, Dunn J. Immersive virtual reality in traumatic brain injury rehabilitation: a literature review. *Neurorehabilitation*. 2018;42(4):441-448.

12. Hickey WF. Basic principles of immunological surveillance of the normal central nervous system. *GLIA*. 2001;36(2):118-124.

13. Webster KM, Sun M, Crack P, O’Brien TJ, Shultz SR, Semple BD. Inflammation in epileptogenesis after traumatic brain injury. *J Neuroinflammation*. 2017;14(1):10.

14. Corps KN, Roth TL, McGavern DB. Inflammation and neuroprotection in traumatic brain injury. *JAMA Neurol*. 2015;72(3):355-362.

15. de Rivero Vaccari JP, Lotocki G, Alonso OF, Bramlett HM, Dietrich WD, Keane RW. Therapeutic neutralization of the NLRP1 inflammasome reduces the innate immune response and improves histopathology after traumatic brain injury. *J Cereb Blood Flow Metab*. 2009;29(7):1251-1261.

16. Werner C, Engelhard K. Pathophysiology of traumatic brain injury. *Br J Anaesth*. 2007;99(1):4-9.

17. Stahel PF, Shohami E, Younis FM, et al. Experimental closed head injury: analysis of neurological outcome, blood-brain barrier dysfunction, intracranial neutrophil infiltration, and neuronal cell death in mice deficient in genes for pro-inflammatory cytokines. *J Cereb Blood Flow Metab*. 2000;20(2):369-380.

18. Wang D, Prameya R, Dorovini-Zis K. Adhesion and migration of polymorphonuclear leukocytes across human brain microvessel endothelial cells are differentially regulated by endothelial cell adhesion molecules and modulate monolayer permeability. *J Neuroimmunol*. 2007;184(1-2):136-148.

19. Wei HL, Ma SQ, Li CX. Deficiency of unc-51 like kinase 1 (Ulkh) protects against mice traumatic brain injury (TBI) by suppression of p38 and JNK pathway. *Biochem Biophys Res Commun*. 2018;503:467-473.

20. Ciesielska N, Sokolowski R, Mazur E, Podhorecka M, Polak-Szabela A, Kędziora-Kornatowska K. Is the Montreal Cognitive Assessment (MoCA) test better suited than the Mini-Mental State Examination (MMSE) in mild cognitive impairment (MCI) detection among people aged over 60? Meta-analysis. *Psychiatr Pol*. 2016;50(5):1039-1052.

21. Wang BR, Zheng HF, Xu C, Sun Y, Zhang YD, Shi JQ. Comparative diagnostic accuracy of ACE-III and MoCA for detecting mild cognitive impairment. *Neuropsychiatr Dis Treat*. 2019;15:2647-2653.

22. Wang BR, Zheng HF, Xu C, Sun Y, Zhang YD, Shi JQ. Comparative diagnostic accuracy of ACE-III and MoCA for detecting mild cognitive impairment. *Neuropsychiatr Dis Treat*. 2019;15:2647-2653.

23. Serrano CM, Sorbara M, Minond A, et al. Rojas MMEY, Ruiz AS, Gravitojo TG. Validation of the Argentine version of the Montreal Cognitive Assessment Test (MOCA): a screening tool for Mild Cognitive Impairment and Mild Dementia in Elderly. *Dement Neuropsychol*. 2020;14(2):145-152.

24. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc*. 2005;53(4):695-699.

25. Morganti-Kossmann MC, Rancan M, Stahel PF, Kossmann T. Inflammatory response in acute traumatic brain injury: a double-edged sword. *Curr Opin Crit Care*. 2002;8(2):101-105.

26. Nonaka M, Chen XH, Pierce JE, et al. Prolonged activation of NF-kappaB following traumatic brain injury in rats. *Neurotrauma*. 1999;16(11):1023-1034.

27. Sherwood ER, Prough DS. Interleukin-8, neuroinflammation, and secondary brain injury. *Crit Care Med*. 2000;28(4):1221-1223.

28. Viviani B, Gardoni F, Marinovich M. Cytokines and neuronal ion channels in health and disease. *Int Rev Neurobiol*. 2007;82:247-263.

29. Cunningham AJ, Murray CA, ONeill LA, Lynch MA, O’Connor JJ. Interleukin-1 beta (IL-1 beta) and tumour necrosis factor (TNF) inhibit long-term potentiation in the rat dentate gyrus in vitro. *Neurosci Lett*. 1996;203(1):17-20.

30. Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. *Proc Natl Acad Sci U S A*. 1995;92(24):11294-11298.

31. Samland H, Huitron-Resendiz S, Maslihah E, Criado J, Henriksen SJ, Campbell IL. Profound increase in sensitivity to glutamatergic—but not cholinergic agonist-induced seizures in transgenic mice with astrocyte production of IL-6. *J Neurosci Res*. 2003;73(2):176-187.

32. Fassbender K, Schneider S, Bertsch T, et al. Temporal profile of release of interleukin-1beta in neurotrauma. *Neurosci Lett*. 2000;284(3):135-138.

33. Shahbazian LM, Jeevanandam M, Petersen SR. Release of proinflammatory cytokines by mitogen-stimulated peripheral blood mononuclear cells from critically ill multiple-trauma victims. *Metabolism*. 1999;48:1397-1401.

How to cite this article: Xu W, Yue S, Wang P, Wen B, Zhang X. Systemic inflammation in traumatic brain injury predicts poor cognitive function. *Immun Inflamm Dis*. 2021;10:e577. doi:10.1002/iid3.577